Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs
January 20, 2020 08:00 ET
|
Tetra Bio-Pharma
Tetra to partner with a Contract Sales Organization (CSO) for both TERPACAN™ and AWAYE™ Tetra expanding sales partnership agreements to the Middle East OTTAWA, Jan. 20, 2020 ...
Tetra Bio-Pharma Receives Favorable Letter of Advice from USA FDA for QIXLEEF
January 13, 2020 08:00 ET
|
Tetra Bio-Pharma
FDA Feedback continues to support the development of QIXLEEF for second- or third-line therapy for adult patients with uncontrolled pain FDA advice consistent with previous feedback paving the way...
Tetra Bio-Pharma Provides Update on U.S. and Canadian Regulatory Activities
December 19, 2019 08:00 ET
|
Tetra Bio-Pharma
Submitted data to U.S. Food and Drug Administration for surrogate endpoint to be used for an Accelerated Approval Two OTC DIN applications pass Health Canada screening phase OTTAWA,...
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Portugal With Azevedos Indústria Farmacêutica, S.A
December 16, 2019 08:00 ET
|
Tetra Bio-Pharma
OTTAWA, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced...
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug HCC011
December 10, 2019 08:00 ET
|
Tetra Bio-Pharma
Orphan Drug Designation qualifies Tetra for certain incentives and benefits, including a 50% tax credit upon approval Tetra to pursue 505(b)(2) NDA pathway and expedited review for its...
Tetra Bio-Pharma Receives FDA Orphan Drug Designation for Hepatocellular Carcinoma
December 04, 2019 08:00 ET
|
Tetra Bio-Pharma
Tetra to launch Phase 2 trial for treatment of hepatocellular carcinoma in Q1 2020 Tetra leverages Caumz™-kit technology to provide a new drug for cancer treatment OTTAWA, Dec. 04,...
Tetra Bio-Pharma Signs Definitive Commercialization Agreement for CAUMZ™ in Mexico With Alternavida S.A.
December 02, 2019 08:00 ET
|
Tetra Bio-Pharma
Alternavida to launch and fund 2 clinical sites in Mexico as part of the clinical research collaboration in the commercialization agreement Collaboration potentially allows Tetra to...
Tetra Bio-Pharma Confirms Submission of Two OTC DIN Applications to Health Canada
November 26, 2019 08:00 ET
|
Tetra Bio-Pharma
OTTAWA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (“TNH”) a wholly owned subsidiary of Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) (TSX-V:TBP) (OTCQB:TBPMF) today announced that...
FDA Approves Advancement of PPP001 Clinical Trial Previously Discontinued
November 25, 2019 08:00 ET
|
Tetra Bio-Pharma
Company to resume clinical trial in advanced cancer patients with uncontrolled painTetra engages leading clinical collaborator to run Plenitude trial in the U.S. OTTAWA, Nov. 25, 2019 (GLOBE...
Tetra Bio-Pharma Secures Financing for Hemp Energy Drink Business
November 18, 2019 08:00 ET
|
Tetra Bio-Pharma
OTTAWA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced its...